Hansa Biopharma AB (HNSAN) Q2 2026 Earnings Report

The call contained several strong strategic and clinical positives — notably the EUR 150M out‑licensing deal (EUR 110M upfront), robust ConfideS and PAES efficacy data supporting improved kidney function and reduced dialysis dependence, and clear U.S. launch preparations with meaningful QoQ sales momentum. Offsetting these positives were near‑term commercial and financial headwinds: slight YoY revenue decline, materially higher SG&A and a widened operating loss, accounting and transition uncertainty related to the SERB transaction, and a higher observed rate of AMR that requires management despite being treatable. On balance, the transformative financing, convincing Phase III/confirmatory data, and launch readiness materially outweigh the short‑term operating and transition challenges, supporting a constructive outlook heading into the regulatory decision period.

The company reiterated actionable near‑term guidance: it is five months from a PDUFA on December 19, 2026 and expects to be launch‑ready for potential U.S. availability in Q1 2027, will pursue conversion from conditional to full EMA approval next year (positive PAES topline; EUR 5m milestone on EMA acceptance), plans to apply for NTAP later this year, and is targeting an IND for HNSA‑5487 before year‑end while continuing to profile and ready the top ~100 U.S. transplant centers (≈80% of volume) via a field team covering all ~200 centers and presenting data at TTS (Sept), ASHI (Oct) and ASN (Oct); financially Q2 revenue was SEK 48.1m (product sales SEK 46.8m; down 2% YoY from SEK 49.1m/47.8m but up 39% vs Q1 2026), SG&A SEK 119m (up 12% vs Q1’s SEK 106m; +SEK 28m vs Q2 2025 SEK 91m), R&D SEK 68m (29% or SEK 28m favorable YoY), operating loss SEK 174m (vs SEK 155m), cash used in operations SEK 104m (vs SEK 112m), cash SEK 553m (≈$57m) excluding the EUR 110m SERB upfront which brings pro‑forma cash to ≈SEK 1.8bn (≈$185m), and headcount 153 (vs 140 in Q2 2025, 122 in Q1 2026); clinical metrics supporting the plan include ConfideS eGFR 51.5 vs 19.3 ml/min (Δ32.2 ml/min; p<0.0001), dialysis‑dependency 5 vs 17 (p=0.0007), patient survival 97% vs 100%, AMR 57% vs 46% with no graft loss from AMR, and an estimated U.S. addressable market of ~$2bn (100,000 on the waitlist, 7,000 with CPRA>98%, ~27,000 transplants/year, ~9,000 kidneys discarded annually).